HOUSTON, Aug. 16 /PRNewswire/ -- Effective August 16, 2006, Daniel S. Lynch was elected to serve as a director of US Oncology Holdings, Inc. and its wholly-owned subsidiary, US Oncology, Inc. Mr. Lynch also has been appointed to the audit committee of the board of directors of each company.
From 2001 until 2005, Mr. Lynch was employed by Imclone Systems Incorporated, a publicly traded biotechnology company, serving as its Chief Financial Officer from 2001 until 2003 and as its Chief Executive Officer and a member of its Board of Directors from 2003 until 2005. Prior to that time, he served as Chief Financial Officer of Derby Cycle Corporation, a designer, manufacturer and marketer of bicycles, from 1999 until 2001, and in various finance capacities at Bristol-Myers Squibb, a pharmaceutical company, from 1984 until 1999.
About US Oncology, Inc.
US Oncology, headquartered in Houston, Texas, is one of the nation's largest cancer treatment and research networks. US Oncology provides extensive services and support to its affiliated cancer care sites nationwide to help them expand their offering of the most advanced treatments and technologies, build integrated community-based cancer care centers, improve their therapeutic drug management programs and participate in many of the new cancer-related clinical research studies. US Oncology is affiliated with 977 physicians operating in 392 locations, including 90 radiation oncology facilities in 34 states. US Oncology also provides a broad range of services to pharmaceutical manufacturers, including product distribution and informational services such as data reporting and analysis.
US Oncology, Inc.CONTACT: Kimberly Rutherford, Corporate Communications of US Oncology,Inc., +1-832-601-6193, or kimberly.rutherford@usoncology.com
Web site: http://www.usoncology.com/
